Keyphrases
Cancer Patients
100%
Third Dose
100%
Serological Response
100%
BNT162b2 COVID-19 Vaccine
100%
Vaccine Dose
66%
Patients with Cancer
50%
BNT162b2
50%
Receptor-binding Domain
50%
Immunoglobulin G
33%
Day Range
33%
Two-dose
33%
Antibody Response
16%
Vaccination
16%
COVID-19
16%
Enzyme-linked Immunosorbent Assay (ELISA)
16%
Small Sample Size
16%
Student's T-test
16%
Immunoglobulin G Antibodies
16%
Titer
16%
Anticancer Treatment
16%
Pfizer-BioNTech
16%
Medicine and Dentistry
Malignant Neoplasm
100%
COVID-19 Vaccine
100%
Booster Dose
100%
Receptor Binding
75%
Immunoglobulin G
50%
Enzyme Linked Immunosorbent Assay
25%
Student T Test
25%
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Immunoglobulin G Antibody
25%
Antibody Response
25%
Biochemistry, Genetics and Molecular Biology
Immunoglobulin G
100%
Binding Domain
100%
Receptor Binding
100%
Enzyme
33%
Sample Size
33%
SARS Coronavirus
33%
Anticancer
33%
Student's t-Test
33%
Titer
33%
Antibody Response
33%
Immunology and Microbiology
COVID-19
100%
Booster Dose
100%
Receptor Binding
75%
Immunoglobulin G
50%
Enzyme-Linked Immunosorbent Assay
25%
Sample Size
25%
Immunoglobulin G Antibody
25%
Antibody Response
25%
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Titer
25%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
COVID-19 Vaccine
100%
Receptor
75%
Immunoglobulin G
50%
Enzyme-Linked Immunosorbent Assay
25%
SARS Coronavirus
25%
Immunoglobulin G Antibody
25%